This is not the most recent version of the article. View current version (17 OCT 2007)

Intervention Protocol

Azathioprine treatment for multiple sclerosis

  1. I Casetta,
  2. G Iuliano

Editorial Group: Cochrane Multiple Sclerosis Group

Published Online: 20 JAN 2003

DOI: 10.1002/14651858.CD003982


How to Cite

Casetta I, Iuliano G. Azathioprine treatment for multiple sclerosis (Protocol). Cochrane Database of Systematic Reviews 2003, Issue 1. Art. No.: CD003982. DOI: 10.1002/14651858.CD003982.

Author Information

*Dr Ilaria Casetta, Clinica Neurologica, Universita degli Studi di Ferrara, Corso Giovecca, 203, Ferrara, 44100, ITALY. ilaria.casetta@libero.it.

Publication History

  1. Published Online: 20 JAN 2003

SEARCH

This is not the most recent version of the article. View current version (17 OCT 2007)

 

Abstract

  1. Top of page
  2. Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows:

The objective of this review is to assess the efficacy and safety of Aza treatment in patients with MS.
The primary questions are whether oral administration of Aza :

  • decreases the frequency of relapses in relapsing-remitting MS
  • increases the probability to remain free from relapses after starting therapy
  • decreases the progression of disability
  • is a safe treatment
Secondary questions are whether oral administration of Aza:
  • reduces the need of steroid treatments
  • reduces the need of hospitalisation